Federal Register of Legislation - Australian Government

Primary content

Specifications as amended, taking into account amendments up to Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Amendment Instrument 2019
Administered by: Attorney-General's
Registered 15 Apr 2019
Start Date 15 Mar 2019
Table of contents.

 

Commonwealth Coat of Arms

Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017

made under subsection 7(1) of the

Safety, Rehabilitation and Compensation Act 1988

Compilation No. 1               

Compilation date:                              15 March 2019

Includes amendments up to:            F2019L00298

 

 

 

 

 

 

 

 

About this compilation

 

This compilation

This is a compilation of the Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017 that shows the text of the law as amended and in force on 15 March 2019 (the compilation date). The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

 

 

  

  

  


Contents

1  Name…………………………………………………………………………………….. 1

2  Commencement………………………………………………………………………….  1

3  Authority………………………………………………………………………………… 1

4  Definitions………………………………………………………………………………..                1

5  Application………………………………………………………………………………. 1

6  Schedules……………………………………………………………………………........1

7  Specification……………………………………………………………………………...1

 

Schedule 1—Specification                                                                                        3

 

Schedule 2—Occupational asthma                                                                          11

 

 


1  Name

                   This instrument is the Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017.

2  Commencement

                   This instrument commences on the earlier of:

(a)    the day after this instrument is registered on the Federal Register of Legislation; and

(b)   1 October 2017.

3  Authority

                   This instrument is made under paragraph 7(1)(b) of the Safety, Rehabilitation and Compensation Act 1988.

4  Definitions

                   In this instrument:

Act means the Safety, Rehabilitation and Compensation Act 1988.

disease has its ordinary meaning.

substance means any natural or artificial substance, whether in the form of a solid, liquid, gas or vapour.

5  Application

                   This instrument applies in relation to a disease that an employee sustains on or after the day this instrument commences.

6  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

7  Specification

                   For the purposes of paragraph 7(1)(b) of the Act, a disease of a kind specified in column 1 of an item of the table in Schedule 1 is a disease related to employment of a kind specified in column 2 of that item.


 

Schedule 1—Specification

 

 

Column 1

Column 2

Item

Disease

Employment

Infectious diseases

 

1          

Anthrax

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts.

2          

Brucellosis

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts; or

(d)     animal waste.

3          

Hepatitis A

Employment involving work with human waste.

4          

Hepatitis B or Hepatitis C

Employment involving work with human body fluids.

5          

Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)

Employment involving work with:

(a)     needles in a healthcare services setting; or

(b)     sharps in a healthcare services setting.

6          

Leptospirosis

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts; or

(d)     animal waste.

7          

Orf

Employment involving work with:

(a)     goats; or

(b)     goat carcasses; or

(c)     sheep; or

(d)     sheep carcasses.

8          

Q-fever

Employment involving work with:

(a)     animals; or

(b)     animal carcasses; or

(c)     animal parts.

9          

Tuberculosis

Employment involving work with:

(a)     animals:

(i)    in a farming setting; or

(ii)   in a veterinarian setting; or

(b)     animal carcasses:

(i)    in a farming setting; or

(ii)   in a veterinarian setting; or

(c)     human corpses:

(i)    in a healthcare services setting; or

(ii)   in a mortuary setting; or

(d)     persons (individuals) in a healthcare services setting.

Malignant diseases

10      

Primary malignant disease of the salivary gland

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

11      

Primary malignant disease of the nasopharynx

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     formaldehyde; or

(b)     wood.

12      

Primary malignant disease of the oesophagus

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

13      

Primary malignant disease of the stomach

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

14      

Primary malignant disease of the colon or rectum

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

15      

Primary malignant disease of the liver

Employment for at least 5 years (whether consecutive or not) involving work with vinyl chloride monomer.

16      

Primary malignant disease of the nasal cavity or para-nasal sinuses

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     nickel; or

(d)     leather; or

(e)     wood.

17      

Primary malignant disease of the larynx

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material; or

(c)     acid mist (strong inorganic).

18      

Primary malignant disease of the lung caused by asbestos

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

19      

Primary malignant disease of the bone

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

20      

Primary malignant disease of the mesothelium

Employment for at least one year (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

21      

Primary malignant disease of the breast

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

22      

Primary malignant disease of the ovary

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

23      

Primary malignant disease of the kidney

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     trichloroethylene.

24      

Primary malignant disease of urothelial tissue lining the urinary tract

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     2-naphthylamine; or

(d)     benzidine; or

(e)     cyclophosphamide; or

(f)      ortho-toluidine; or

(g)     polycyclic aromatic hydrocarbons during aluminium production.

25      

Primary malignant disease of the brain

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

26      

Primary malignant disease of the thyroid

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

27      

Primary leukaemia (excluding chronic lymphatic leukaemia)

Employment for at least 2 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation; or

(c)     benzene; or

(d)     butadiene; or

(e)     cyclophosphamide; or

(f)      formaldehyde.

28      

Primary non-Hodgkins lymphoma

Employment for at least 2 years (whether consecutive or not) involving work with:

(a)     equipment that produces ionising radiation; or

(b)     substances that emit ionising radiation.

Diseases of the nervous system

29      

Parkinson’s disease

Employment for at least one year (whether consecutive or not) involving work with manganese.

30      

Peripheral neuropathy

Employment for at least one year (whether consecutive or not) involving work with:

(a)     acrylamide; or

(b)     arsenic; or

(c)     carbon disulphide; or

(d)     lead; or

(e)     mercury; or

(f)      n-hexane; or

(g)     organophosphates; or

(h)     trichloroethylene.

Respiratory diseases

 

31      

Occupational asthma

Employment for at least 4 weeks (whether consecutive or not) involving work with an agent or thing specified in column 2 of an item of the table in Schedule 2.

32      

Coal workers’ pneumoconiosis

Employment for at least 5 years (whether consecutive or not) involving work with coal.

33      

Asbestosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     asbestos; or

(b)     asbestos-containing material.

34      

Silicosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     material containing crystalline silica; or

(b)     silica.

35      

Other pneumoconiosis

Employment for at least 5 years (whether consecutive or not) involving work with:

(a)     aluminium; or

(b)     barium; or

(c)     beryllium; or

(d)     cobalt; or

(e)     iron oxide; or

(f)      tin; or

(g)     tungsten.

36      

Byssinosis

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     unprocessed cotton; or

(b)     unprocessed flax; or

(c)     unprocessed hemp; or

(d)     unprocessed sisal.

37      

Extrinsic allergic alveolitis

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     feathers; or

(b)     grain; or

(c)     hay; or

(d)     straw.

Hepatic disease

38      

Non-infectious hepatitis

Employment involving work with:

(a)     acrylonitrile; or

(b)     alcohols; or

(c)     amino-derivatives of benzene; or

(d)     antimony; or

(e)     aromatic hydrocarbons; or

(f)      arsenic; or

(g)     benzene; or

(h)     benzoquinone; or

(i)       beryllium; or

(j)      cadmium; or

(k)     carbon disulphide; or

(l)       carbon monoxide; or

(m)   chromium; or

(n)     copper; or

(o)     fluorine; or

(p)     glycols; or

(q)     hexane; or

(r)      hydrogen cyanide; or

(s)      hydrogen sulphide; or

(t)      ketones; or

(u)     lead; or

(v)     manganese; or

(w)    mercury; or

(x)     methylene chloride; or

(y)     mineral acids; or

(z)     nitric acid esters; or

(za)         organochlorine compounds; or

(zb)         organophosphate; or

(zc)         osmium; or

(zd)         oxides of nitrogen; or

(ze)         ozone; or

(zf)          phosgene; or

(zg)         phosphorus; or

(zh)         selenium; or

(zi)          styrene; or

(zj)          thallium; or

(zk)         tin; or

(zl)          toluene; or

(zm)        toxic halogen derivatives of aliphatic; or

(zn)         toxic nitro-derivatives of benzene; or

(zo)         vanadium; or

(zp)         zinc.

Skin diseases

 

39      

Irritant contact dermatitis

Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:

(a)     alcohols; or

(b)     cutting fluids; or

(c)     cleaners; or

(d)     degreasers; or

(e)     disinfectants; or

(f)      liquids (frequent contact); or

(g)     liquids (prolonged contact); or

(h)     petroleum products; or

(i)       soaps; or

(j)      solvents.

40      

Allergic contact dermatitis

Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:

(a)     2,5-diaminotoluene sulfate; or

(b)     4-phenylenediamine base; or

(c)     ammonium persulfate; or

(d)     cobalt chloride; or

(e)     cocamide diethanolamide; or

(f)      coconut diethanolamide; or

(g)     colophonium/colophony/rosin; or

(h)     diazolidinyl urea; or

(i)       epoxy resin; or

(j)      formaldehyde; or

(k)     fragrance mix I:

(i)         amylcinnamaldehyde; or

(ii)        cinnamic alcohol; or

(iii)       cinnamic aldehyde;

(iv)       eugenol; or

(v)        geraniol; or

(vi)       hydroxycitronellal; or

(vii)      isoeugenol; or

(viii)     oakmoss absolute; or

(l)       fragrance mix II:

(i)         citral; or

(ii)        citronellol; or

(iii)       coumarin; or

(iv)       farnesol; or

(v)        hexyl cinnamic aldehyde; or

(vi)       hydroxyisohexyl 3-cyclohexene carboxaldehyde; or

(m)   glyceryl monothioglycolate; or

(n)     hydroxyethyl methacrylate; or

(o)     mercaptobenzothiazole; or

(p)     methyl chloroisothiazolinone; or

(q)     mixture of methylchloroisothiazolinone and methylisothiazolinone; or

(r)      nickel sulfate; or

(s)      potassium dichromate; or

(t)      quaternium 15; or

(u)     thiuram mix:

(i)         tetramethylthiuramdisulfide; or

(ii)        tetramethylthiuram monosulfide; or

(iii)       tetraethylthiuram disulfide.

41      

Occupational vitiligo

Employment for at least 4 weeks (whether consecutive or not) involving work with:

(a)     hydroquinone; or

(b)     monobenzyl ether of hydroquinone; or

(c)     monobutyl ether of hydroquinone; or

(d)     para-amylphenol; or

(e)     para-tertiary-butylcatechol; or

(f)      para-tertiary-butylphenol.

Musculoskeletal diseases

42      

Raynaud’s disease

Employment for at least 12 weeks (whether consecutive or not) involving work with:

(a)     powered equipment that produces vibration; or

(b)     powered tools that produce vibration.

43      

Bursitis at the elbow or knee

Employment for at least 6 months (whether consecutive or not) involving a work activity that:

(a)     for bursitis at the elbow:

(i)         involves prolonged external friction at or about the elbow; or

(ii)        involves prolonged external pressure at or about the elbow; or

(iii)       involves recurrent external friction at or about the elbow; or

(iv)       involves recurrent external pressure at or about the elbow; or

(b)     for bursitis at the knee:

(i)         involves prolonged external friction at or about the knee; or

(ii)        involves prolonged external pressure at or about the knee; or

(iii)       involves recurrent external friction at or about the knee; or

(iv)       involves recurrent external pressure at or about the knee.

Acute diseases

44      

Acute poisoning or toxicity affecting the heart, lungs, liver, kidney, nervous system or blood

The same as for item 38.


 

Schedule 2—Occupational asthma

 

 

Column 1

Column 2

Item

Class of agent or thing

Specified agent or thing

1          

Arthropods

(a)     acarian; or

(b)     barn mite; or

(c)     caddisfly; or

(d)     cricket; or

(e)     Ephestia kuehniella (Mediterranean flour moth); or

(f)      fowl mite; or

(g)     fruit fly; or

(h)     grain mite; or

(i)       flour mite; or

(j)      lesser mealworm; or

(k)     locust; or

(l)       sheep blowfly; or

(m)   silkworm.

2          

Acids

(a)     dodecanedioic acid; or

(b)     glacial acetic acid; or

(c)     hydrochloric acid; or

(d)     peroxyacetic acid; or

(e)     sulphuric acid; or

(f)      sulphur dioxide.

3          

Acrylates

(a)     acrylic acid; or

(b)     cyanoacrylates; or

(c)     methyl methacrylate; or

(d)     polymethyl methacrylate; or

(e)     trimethylolpropane triacrylate/2-hydroxypropyl acrylate.

4          

Aldehydes

(a)     formaldehyde; or

(b)     gluteraldehyde; or

(c)     paraformaldehyde; or

(d)     urea formaldehyde.

5          

Amines

(a)     aminoethyl ethanolamine; or

(b)     diethanolamine; or

(c)     dimethylethanolamine; or

(d)     ethanolamines; or

(e)     ethylenediamine; or

(f)      monoethanolamine; or

(g)     surfactant-specific amines; or

(h)     triethanolamine; or

(i)       triethylenetetramine; or

(j)      trimethylhexane-1; or

(k)     6-diamine/isophorondiamine mixture.

6          

Ammonias

(a)     anhydrous ammonia; or

(b)     ammonium hydroxide; or

(c)     ammonia solution 10%; or

(d)     ammonia solution 29%.

7          

Anhydrides

(a)     hexahydrophthalic anhydride; or

(b)     himic anhydride; or

(c)     maleic anhydride; or

(d)     methyl tetrahydrophthalic; or

(e)     anhydride; or

(f)      phthalic anhydride; or

(g)     tetrachlorophthalic anhydride; or

(h)     trimellitic anhydride.

8          

Bio-aerosols

(a)     Alternaria; or

(b)     Chrysonilia sitophilia; or

(c)     Neurospora; or

(d)     Penicillium; or

(e)     cutting oils.

9          

Biological enzymes

(a)     Bacillus subtilis enzymes; or

(b)     bromelain; or

(c)     egg lysozyme; or

(d)     esperase; or

(e)     flaviastase; or

(f)      fungal amylase; or

(g)     fungal amyloglucosidase; or

(h)     fungal hemicellulose; or

(i)       pancreatin; or

(j)      papain; or

(k)     pepsin; or

(l)       trypsin.

10      

Epoxy

(a)     epoxy; or

(b)     epoxy adhesive.

11      

Ethylene oxide

ethylene oxide.

12      

Flours

(a)     buckwheat flour; or

(b)     rye flour; or

(c)     soya flour; or

(d)     wheat flour.

13      

Flowers

(a)     baby’s breath; or

(b)     freesia; or

(c)     Limonium tataricum; or

(d)     sunflower.

14      

Foods

(a)     Brazil ginseng; or

(b)     castor bean; or

(c)     chamomile; or

(d)     cinnamon; or

(e)     Dioscorea batatas (Chinese yam); or

(f)      egg protein; or

(g)     fenugreek; or

(h)     garlic dust; or

(i)       green beans; or

(j)      guar; or

(k)     hops; or

(l)       paprika; or

(m)   pectin; or

(n)     rose hips; or

(o)     soybean lecithin; or

(p)     tea; or

(q)     thiamine (vitamin B); or

(r)      thyme.

15      

Industrial cleaning and sterilising agents

(a)     alkyl dimethyl benzyl ammonium chloride; or

(b)     benzyl-C10-16-alkyldimethyl, chlorides; or

(c)     benzyl-C12-16-alkyldimethyl, chlorides; or

(d)     benzyl-C12-18-alkyldimethyl, chlorides; or

(e)     benzyl-C16-18-alkyldimethyl, chlorides; or

(f)      benzyldimethylstearyl ammonium chloride; or

(g)     cetalkonium chloride; or

(h)     chlorhexidine; or

(i)       chlorine; or

(j)      dialkyl methyl benzyl ammonium chloride; or

(k)     dicumyl-peroxide; or

(l)       dodecyl dimethyl ammonium chloride; or

(m)   dimethyl ethyl benzyl ammonium chloride; or

(n)     dodecyl-dimethylbenzylammonium; or

(o)     fluorine; or

(p)     n-alkyl dimethyl benzyl ammonium chloride; or

(q)     persulphate salts; or

(r)      sodium hypochlorite; or

(s)      sodium metabisulfite.

16      

Isocyanates

(a)     diisocyanates; or

(b)     hexamethylene diisocyanate prepolymers; or

(c)     isocyanates; or

(d)     toluene diisocyanate prepolymers.

17      

Latex

(a)     latex; or

(b)     natural rubber.

18      

Medications

(a)     ampicillin; or

(b)     amprolium; or

(c)     cimetidine; or

(d)     codeine; or

(e)     colistin; or

(f)      hydralazine; or

(g)     ipecacuanha; or

(h)     hydrocodone; or

(i)       isonicotinic acid hydrazide; or

(j)      methyldopa; or

(k)     morphine; or

(l)       opiate compounds; or

(m)   oxycodone; or

(n)     papaverine; or

(o)     penicillamine; or

(p)     penicillins; or

(q)     phenylglycine acid chloride; or

(r)      psyllium; or

(s)      salbutamol intermediate; or

(t)      spiramycin; or

(u)     tetracycline; or

(v)     thebaine; or

(w)    tylosin tartrate; or

(x)     vancomycin.

19      

Metals

(a)     aluminium; or

(b)     aluminium chloride; or

(c)     aluminium oxide; or

(d)     aluminium compounds; or

(e)     ammonium dichromate; or

(f)      ammonium hexachloroplatinate (IV); or

(g)     chromium; or

(h)     chromium, metal; or

(i)       chromium, hexavalent; or

(j)      chromium, non-hexavalent; or

(k)     cobalt; or

(l)       cobalt compounds; or

(m)   nickel; or

(n)     nickel compounds; or

(o)     platinum; or

(p)     rhodium; or

(q)     soluble halogenated platinum compounds; or

(r)      titanium oxide/dioxide; or

(s)      tributyl tin oxide; or

(t)      tungsten carbide; or

(u)     tungsten carbide/cobalt; or

(v)     vanadium; or

(w)    welding fumes – gas metal arc welding on uncoated mild steel; or

(x)     welding fumes – stainless steel; or

(y)     stainless steel; or

(z)     zinc oxide.

20      

Other reactive chemicals

(a)     chlorofluorocarbon refrigerants heated; or

(b)     fluoride; or

(c)     furfuryl alcohol mixed with a catalyst; or

(d)     isolyzer; or

(e)     polyethylene terephthalate/polybutylene terephthal; or

(f)      polyfunctional aziridine; or

(g)     polypropylene heated; or

(h)     polyvinyl chloride heated; or

(i)       polyvinyl chloride non-heated; or

(j)      polyvinyl chloride thermally degraded; or

(k)     radiographic fixative; or

(l)       resin containing furfuryl alcohol; or

(m)   styrene; or

(n)     trigylicidyl isocyanurate.

21      

Pesticides

(a)     3-amino-5-mercapto-1;2;4-triazole; or

(b)     acephate; or

(c)     chloramine T; or

(d)     chlorothalonil (bravo, echo); or

(e)     diazinon; or

(f)      dimethoate; or

(g)     fenthion; or

(h)     malathion; or

(i)       nemacur; or

(j)      piperazine; or

(k)     piperazine citrate; or

(l)       piperazine hydrochloride; or

(m)   pyrethrins; or

(n)     pyrfon; or

(o)     safrotin; or

(p)     tetramethrin.

22      

Plants and sensitising agents or irritants derived from plants

(a)     almond dust; or

(aa) Arabidopsis thaliana; or

(b)     Chlorella algae; or

(c)     gum arabic; or

(d)     henna; or

(e)     kapok; or

(f)      linseed oilcake; or

(g)     Pinellia ternata; or

(h)     quillaja bark; or

(i)       rice dust; or

(j)      tall oil crude; or

(k)     tall oil – rosin; or

(l)       tobacco leaf; or

(m)   tragacanth; or

(n)     turpentine; or

(o)     Vicia sativa (vetch); or

(p)     weeping fig.

23      

Reactive dyes

(a)     Cibachrome Brilliant Scarlet 32; or

(b)     Drimarene Brilliant Blue K-BL; or

(c)     Drimarene Brilliant Yellow K-3GL; or

(d)     Lanasol Yellow 4G; or

(e)     Levafix Brilliant Yellow E36; or

(f)      Methyl Blue; or

(g)     Rifacion Orange HE 2G; or

(h)     Rifafix Yellow 3 RN; or

(i)       Rifazol Black GR; or

(j)      Rifazol Brilliant Orange 3R.

24      

Sensitising agents or irritants derived from animals

(a)     bat guano; or

(b)     bovine serum albumin; or

(c)     casein; or

(d)     cat antigens; or

(e)     chicken antigens; or

(f)      cow antigens; or

(g)     frog antigens; or

(h)     guinea pig antigens; or

(i)       lactoserum; or

(j)      mice antigens; or

(k)     pig antigens; or

(l)       rabbit antigens; or

(m)   rat antigens.

25      

Sensitising agents or irritants derived from fish or shellfish

(a)     Anisakis simplex (herring worm) antigens; or

(b)     clam antigens; or

(c)     crab antigens; or

(d)     cuttlefish antigens; or

(e)     fishmeal; or

(f)      nacre dust; or

(g)     octopus antigens; or

(h)     prawn antigens; or

(i)       red soft coral antigens; or

(j)      salmon antigens; or

(k)     shrimp meal; or

(l)       trout antigens.

26      

Soldering fluxes

(a)     colophony soldering flux; or

(b)     alkyl aryl polyether soldering flux; or

(c)     zinc soldering flux.

27      

Wood

(a)     Triplochiton scleroxylon (African maple); or

(b)     Acacia melanoxylon (blackwood); or

(c)     Sequoia sempervirens (California redwood); or

(d)     Juglans olanchana (Central American walnut); or

(e)     Thuja occidentalis (eastern white cedar); or

(f)      Shoreal sp. (mahogany); or

(g)     Quercus robur (oak); or

(h)     Thuja lpicata (western red cedar).

 

 

 

 


 

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history. 

Endnote 2—Abbreviation key

 

o = order(s)

ad = added or inserted

Ord = Ordinance

am = amended

orig = original

amdt = amendment

par = paragraph(s)/subparagraph(s)

c = clause(s)

    /sub‑subparagraph(s)

C[x] = Compilation No. x

pres = present

Ch = Chapter(s)

prev = previous

def = definition(s)

(prev…) = previously

Dict = Dictionary

Pt = Part(s)

disallowed = disallowed by Parliament

r = regulation(s)/rule(s)

Div = Division(s)

 

exp = expires/expired or ceases/ceased to have

reloc = relocated

    effect

renum = renumbered

F = Federal Register of Legislation

rep = repealed

gaz = gazette

rs = repealed and substituted

LA = Legislation Act 2003

s = section(s)/subsection(s)

LIA = Legislative Instruments Act 2003

Sch = Schedule(s)

(md) = misdescribed amendment can be given

Sdiv = Subdivision(s)

    effect

SLI = Select Legislative Instrument

(md not incorp) = misdescribed amendment

SR = Statutory Rules

    cannot be given effect

Sub‑Ch = Sub‑Chapter(s)

mod = modified/modification

SubPt = Subpart(s)

No. = Number(s)

underlining = whole or part not

 

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2017

3 October 2017

(F2017L01318)

1 October 2017

-

Safety, Rehabilitation and Compensation (Specified Diseases and Employment) Amendment Instrument 2019

14 March 2019

(F2019L00298)

15 March 2019

Sch 1 (item 3)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Sch 1, Item 43, column 2, par (b)(iv)

am F2019L00298

Sch 2, Item 22, column 2 par (a)

am F2019L00298

Sch 3

Rep LA s 48C